{
  "report_rows": [
    {
      "kpi": "Revenue",
      "prediction": "BEAT",
      "answer": "pred ~$2.87B vs. cons $2.82B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$2.55 vs. cons $2.48",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "da Vinci procedure growth",
      "prediction": "BEAT",
      "answer": "pred ~15.5% vs. cons 15.0%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Worldwide da Vinci procedure growth",
      "prediction": "BETTER",
      "answer": "guide ~14.0%-16.0% vs. cons 13.5%-15.5% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted gross margin",
      "prediction": "UNCHANGED",
      "answer": "guide ~67.5%-68.5% vs. cons 67.5%-68.5% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted operating-expense growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~11%-14% vs. cons 11%-14% (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 5.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 4.0,
  "day5_path": "FADE",
  "day5_rationale": "Day-1 residual ~+5.5% vs. five-day residual ~+4.0%: resilient procedures should reverse part of the HCA-driven selloff, but only a modest guidance increase implies roughly 14%-15% second-half procedure growth versus about 16% in the first half, limiting estimate revisions and causing some initial gain to fade.",
  "day5_confidence": "MEDIUM"
}